Objectives: Administration of eicosapentaenoic acid and docosahexanoic acid, omega-3 fatty acids in fish oil, has been associated with improved patient outcomes in acute lung injury when studied in a commercial enteral formula. However, fish oil has not been tested independently in acute lung injury. We therefore sought to determine whether enteral fish oil alone would reduce pulmonary and systemic inflammation in patients with acute lung injury.
T here are 200,000 U.S. cases of acute lung injury (ALI) and the acute respiratory distress syndrome each year with a case fatality of 30% to 40% (1, 2) . Although low tidal volume ventilation improves survival, there are currently no pharmacologic treatments for ALI. Several recent studies in animals and humans, however, suggest that omega-3 fatty acids (-3s) may be beneficial in ALI (3) (4) (5) (6) (7) (8) .
ALI pathogenesis is thought to result from massive activation of the proinflammatory response, including release of inflammatory mediators such as the eiconsanoids (9) . The most proinflammatory eicosanoids are metabolized from arachidonic acid and include two-series prosta-glandins and thromboxanes and four-series leukotrienes (Fig. A in supplemental digital content [Supplemental Digital Content 1, http://links.lww.com/CCM/A241], which displays human -3 and -6 fatty acid metabolism [PG, prostaglandin; TX, thromboxane; LT, leukotriene; COX, cyclooxygenase; LOX, lipoxygenase]) (10, 11) . They play a prominent role in fever, vascu-lar permeability, vasodilatation, platelet aggregation, leukocyte adhesion, and cytokine production (12) (13) (14) .
Eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA) are two essential -3s found in fish oil (Figure A in supplemental digital content [Supplemental Digital Content 1, http://links.lww.com/CCM/ A241], which displays human -3 and -6 fatty acid metabolism [PG, prostaglandin; TX, thromboxane; LT, leukotriene; COX, cyclo-oxygenase; LOX, lipoxygenase]) that reduce inflammatory eicosanoid production through a variety of anti-inflammatory mechanisms (11, (15) (16) (17) (18) . Additionally, the novel anti-inflammatory mediators resolvins and protectins are derived from EPA and DHA (19, 20) .
EPA and DHA have been combined with ␥-linoleic acid (an -6 fatty acid) and several antioxidants into a commercial high-fat/low-carbohydrate enteral formula. In industry-sponsored animal studies of lung injury, this commercial formula had biological and physiologic benefits (3-5, 21, 22) . Prior studies of enteral -3s in critically ill humans have all used this commercial formula. Five small randomized controlled trials (RCTs) have been performed in patients with ALI and sepsis (6 -8, 23, 24) ; one is published only in abstract form and one is unpublished. The control groups in all five trials received a high-fat/low-carbohydrate enteral formula isonitrogenous with the fish oil-containing formula but free from fish oil. A meta-analysis of these five trials suggested that the fish oil/␥linoleic acid/antioxidant formula was associated with reduced mortality, intensive care unit (ICU) length of stay, and duration of mechanical ventilation (25) .
Interpretation of these data, however, is difficult because: 1) control groups received a high-fat formula that is not standard of care in critically ill patients and may be proinflammatory; and 2) independent effects of -3s cannot be assessed because the feeding formula contains ingredients other than fish oil. Furthermore, because critically ill patients commonly receive Ͻ50% of prescribed caloric need enterally, inclusion of a pharmaconutrient in an enteral formula could result in inadequate delivery of the nutrient (26) . To determine whether EPA and DHA have an independent therapeutic benefit in patients with ALI, we conducted a phase II RCT of enteral fish oil (alone and separate from any enteral feeding) vs. placebo.
MATERIALS AND METHODS

Participants and Study Setting.
A detailed methods description is in the supplemental digital content (Supplemental Digital Content 2, http://links.lww.com/CCM/A242). Participants were enrolled from 2006 to 2008 at five North American centers. All human subject committees and a data safety monitoring board approved the trial, which was registered as NCT00351533. All intubated, mechanically ventilated patients Ͼ17 yrs of age meeting ALI criteria as defined by the American-European Consensus Conference (27) (ratio of partial pressure of arterial oxygen to fraction of inspired oxygen Յ300, chest radiograph demonstrating bilateral infiltrates consistent with pulmonary edema, and no evidence of left heart failure causing the infiltrates) were eligible for enrollment. Table 1 
lists exclusion criteria.
Study Design and Intervention. After informed consent and within 48 hrs of ALI onset, participants were randomized in a 1:1 ratio to receive enteral fish oil (7.5 mL every 6 hrs equaling 9.75 g EPA and 6.75 g DHA daily) or 0.9% saline. Computer-generated random allocation in permuted blocks of four was performed by Investigational Drug Services at Harborview Medical Center in Seattle, WA, and randomization was stratified by study site and the presence of trauma. Sequentially numbered, opaque, sealed envelopes were sent to each site. After enrolling a new patient, research pharmacists at each site opened the next envelope in the sequence.
We used a concentrated liquid fish oil (Ultimate Omega; Nordic Naturals, Watsonville, CA) manufactured in a single batch. Independent analysis before study start found the expected concentration of EPA and DHA and no heavy metal contaminants. Both fish oil and placebo were dispensed in opaque brown syringes by research pharmacists, and the exterior of all syringes was brushed with fish oil to preserve blinding. Only research pharmacists were aware of group assignment. Study participants and personnel remained blinded throughout the trial.
Patients received study drug for 14 days or until death, ICU discharge, or 48 hrs of unassisted breathing, whichever occurred first. All subjects were ventilated according to local protocols mimicking the ARDS Network low tidal volume ventilation protocol (28) . Enteral or parenteral feeding was at the discretion of treating clinicians.
Procedures and Outcomes. Bronchoalveolar lavage fluid (BALF) and plasma were obtained at study entry (day 0) and on days 4 Ϯ 1 and 8 Ϯ 1. The second and third bronchoalveolar lavages did not occur if participants were extubated or did not meet safety criteria for bronchoscopy. Serum was collected on day 5 for EPA and DHA measurement. Adverse events were monitored daily.
BALF interleukin (IL)-8 was chosen as our primary end point because it is the dominant neutrophil chemoattractant in ALI (29) and is decreased in patients receiving low tidal volume ventilation (30) , an intervention known to improve survival in ALI (28) . Additionally, in the only prior trial of the fish oil-containing enteral formula to perform bronchoalveolar lavages, patients in the intervention group had reduced BALF IL-8 compared with the control group (6) . Secondary outcomes included BALF IL-6, leukotriene B 4 (LTB 4 ), monocyte chemotactic protein-1, and neutrophil count; plasma IL-8, LTB 4 , IL-6, von Willebrand factor (vWF), and surfactant protein-D; lung compliance; and oxygenation. IL-6 activates leukocytes, affects the acute phase response, and levels correlate with ALI severity (31) . LTB 4 is also a potent neutrophil chemoattractant produced by alveolar macrophages (32) and its production is presumably directly inhibited by -3s. Monocyte chemotactic protein-1 is a monocyte chemoattractant, and increasing levels have been associated with both worse lung injury and persistent ALI (33) . Surfactant Table 1 . Exclusion criteria 1. Met acute lung injury criteria for Ն48 hrs 2. Expected intensive care unit length of stay Յ48 hrs 3. Expected survival Յ28 days from underlying preintensive care unit condition 4. Unable to undergo bronchoalveolar lavage at enrollment (ratio of partial pressure of arterial oxygen to fraction of inspired oxygen Ͻ80 on 100% FIO 2 , endotracheal tube too small, marked cardiovascular instability, intracranial pressure Ն20 mm Hg) 5. Unable to obtain enteral access 6. Pregnant 7. Metastatic cancer 8. Acquired immunodeficiency syndrome with CD4 Ͻ200 9. Postcardiac arrest with suspected significant anoxic brain injury 10. Past bone marrow or solid organ transplant (lung, heart, liver, pancreas, or kidney) 11. Platelets Ͻ30,000/mm 3 12. Active bleeding 13. International normalized ratio Ͼ3.0 14. Receiving recombinant human activated protein C 15. History of ventricular tachycardia or fibrillation 16. Known allergy to fish 17. Received enteral formula containing -3 fatty acids during intensive care unit stay protein-D is a biomarker of alveolar epithelial injury and vWF is a marker of endovascular injury; both have been associated with increased mortality in ALI (34 -38) .
Although the trial was not powered to detect differences in clinical outcomes, we measured organ failure with the multiple organ dysfunction score (39), ventilator-free and ICU-free days during the first 28 days (40), hospital length of stay, and hospital and 60day mortality.
Measurements. Biomarker assays were performed in Seattle, WA. IL-8, IL-6, and monocyte chemotactic protein-1 concentrations were determined using Luminex beadbased immunoassays (R&D Systems, Minneapolis, MN) (41) . LTB4 was measured by enzyme immunoassay (Cayman Chemical, Ann Arbor, MI) after solid phase extraction (42) . Surfactant protein-D and vWF were measured by enzyme-linked immunosorbent assays (BioVendor, Candler, NC; and Diagnostica Stago, Parsippany, NJ). For serum EPA and DHA measurement, lipids were extracted using methods described previously (43) and phospholipids were separated by thin layer chromatography (44) . Fatty acid methyl esters were prepared using methods of Lepage (45) and separated with gas chromatography.
Sample Size and Statistical Analyses. The primary outcome was a Ն50% reduction in BALF IL-8 in the intervention compared with the control group, measured as the change from baseline to day 4 Ϯ 1 and day 8 Ϯ 1. With ␣ ϭ 0.05 and ␤ ϭ 0.2 (80% power), we calculated that 26 patients per group were needed if participants underwent two bronchoalveolar lavages. Because low tidal volume ventilation is now standard, we assumed biomarker levels would be lower than historical data. We therefore conservatively estimated that our study required 45 patients per group. The data safety monitoring board performed interim safety analyses after 30 and 60 enrolled patients.
Baseline characteristics were analyzed with t, chi-square, and Fisher's exact tests. Because biomarker data are commonly nonparametric, we used Mann-Whitney U tests to compare changes from baseline to day 4 and to day 8. Additionally, given the longitudinal nature of the biomarker data, we also used mixed model linear regression analyses with log transformation of inflammatory biomarker data and random intercepts and slopes for each patient.
Clinical outcomes were analyzed in an intent-to-treat fashion. Worst multiple organ dysfunction score (39), ventilator-free days, ICU-free days, and hospital length of stay were analyzed with t tests and Mann-Whitney U tests. Hospital and 60-day mortality were compared with chi-square tests. Planned a priori subgroup analyses were performed on participants whose ALI risk factor was trauma vs. other. All analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC). Re-ported p values are two-sided and are uncorrected for multiple comparisons.
RESULTS
Participants
During the enrollment period, 2,037 patients met initial screening criteria. Of these, 1,947 were excluded for reasons shown in Figure 1 . Forty-one patients were randomized to receive fish oil and 49 to receive placebo. One patient in the fish oil group was extubated before the first bronchoalveolar lavage was performed, did not receive any fish oil, and declined further participation but did allow collection of clinical follow-up data. One patient in the placebo group underwent the first bronchoal-veolar lavage but was subsequently withdrawn by his or her physician. This patient did not receive any placebo doses but did consent to collecting further clinical data. Another patient in the placebo group was withdrawn by his or her family before the second bronchoalveolar lavage because the decision had been made to remove life-sustaining therapies; no laboratory or clinical data were collected beyond that time. One patient in the fish oil group and three patients in the placebo group were lost to follow-up between hospital discharge and day 60.
Baseline Characteristics
Demographic and physiological characteristics of the two groups were well balanced at baseline ( Table 2 ). The groups were similar with regard to age, gender, race, ethnicity, admission diagnosis, Acute Physiology and Chronic Health Evaluation II score (46) , partial pressure of arterial oxygen to fraction of inspired oxygen ratio, tidal volume, plateau pressure, and positive end expiratory pressure. However, patients receiving fish oil more commonly had aspiration as an ALI risk factor (29.3% vs. 10.2%, p ϭ .02) and had a higher lung injury score (2.8 Ϯ 0.5 vs. 2.4 Ϯ 0.7) (47).
Protocol Compliance
Participants in the intervention and placebo groups received a median of 29 (interquartile range [IQR], 16 -48) and 36 doses (IQR, 17-55), respectively. Patients receiving at least 7 days of study drug numbered 26 of 41 (63.4%) in the fish oil group and 32 of 49 (65.3%) in the placebo group (p ϭ .85). Ten of 41 (24.4%) participants receiving fish oil and 19 of 49 (38.8%) receiving placebo completed the full 14 days of study drug (p ϭ .15) with study drug being stopped as a result of death, unassisted breathing for Ն48 hrs, or ICU discharge as per protocol. There were 37 total individual doses (mean 0.90 per participant) missed in the active group and 35 missed (mean 0.71 per participant) in the placebo group. Reasons for missed doses included: 1) having procedure out of ICU; 2) not receiving any enteral intake; 3) emesis; 4) nursing error; and 5) pharmacy error. In the fish oil and placebo groups, respectively, 30 of 41 (73.2%) and 36 of 49 (73.5%) patients underwent at least two bronchoalveolar lavages (p ϭ .97). Fifteen of 41 patients (36.6%) receiving fish oil and 26 of 49 (53.1%) receiving placebo (p ϭ .12) underwent all three bronchoalveolar lavages.
Participants receiving fish oil had higher serum EPA and DHA levels on study day 5 than did participants receiving placebo. Median serum EPA was 31.9 mg/L (IQR, 24.1-59.7 mg/L) in the fish oil group and 2.4 mg/L (IQR, 1.5-6.3 mg/L) in the placebo group (p Ͻ .0001). Median DHA concentration was 24.1 mg/L (IQR, 15.8 -39.8 mg/L) vs. 12.8 mg/L (IQR, 9.1-17.9 mg/L) in the fish oil and placebo groups, respectively (p ϭ .0009).
Outcomes
Biomarker Outcomes. There was no statistically significant difference in the change in bronchoalveolar lavage IL-8 from baseline to day 4 or from baseline to day 8 between the fish oil and placebo groups (Table 3) . Likewise, there were no significant differences in changes among bronchoalveolar lavage IL-6, monocyte chemotactic protein, and neutrophil count on either day 4 or day 8. We did find that bronchoalveolar lavage LTB 4 concentration increased from baseline to day 4 in the fish oil group and decreased in the placebo group (p ϭ .04 without adjustment for multiple comparisons). See Table A Similarly, there were no appreciable differences in plasma IL-8, IL-6, surfactant protein-D, or vWF between the two groups when comparing changes between baseline to day 4 and baseline to day 8 (Table 4 ). Again, we found that plasma LTB 4 increased from baseline to day 4 in the fish oil group and decreased in the placebo group (p ϭ .002). See Table B in the supplemental digital content (Supplemental Digital Content 2, http://links.lww.com/CCM/A242) for plasma biomarker values.
As secondary analyses, we also performed longitudinal analyses using linear regression mixed modeling with logtransformed biomarker levels and random intercepts and slopes for each participant (data not shown). No differences were found in any bronchoalveolar lavage or plasma biomarkers.
We performed planned a priori subgroup analyses for participants whose ALI risk factor was trauma and those with ). There were no differences in changes in BALF inflammatory mediator levels between the two groups within either trauma or nontrauma patients. However, BALF IL-8 levels were generally greater in trauma than nontrauma patients. When plasma biomarkers were examined, we found that changes in LTB 4 between baseline and day 4 were significantly different in both trauma and nontrauma subgroups with greater increases in those subgroups randomized to fish oil than to placebo. Similarly, the increase in plasma vWF between baseline and day 4 was also greater in trauma patients receiving fish oil than in trauma patients receiving placebo.
Cointerventions and Physiological Outcomes. In this study, enteral feeding was determined by treating clinicians. Participants in the fish oil and placebo groups began receiving enteral feeding 1.8 Ϯ 1.2 and 1.9 Ϯ 1.3 days after ICU admission, respectively (p ϭ .65). Mean caloric intake during the study's first week was 7362 Ϯ 3800 kcal in the fish oil group and 7495 Ϯ 3831 kcal in the placebo group (p ϭ .87). Because propofol is delivered in a lipid carrier, we also recorded its use. Median volume of propofol received during the first week was 62 mL (IQR, 0 -555 mL) and 233 mL (IQR, 0 -980 mL) in the fish oil and placebo groups, respectively (p ϭ .18).
Results of physiological outcomes are shown in Table 5 . There were no appreciable differences in tidal volume per kilogram predicted body weight, oxygenation, positive end expiratory pressure, or plateau pressure between the groups at day 4 or day 8. We did find that patients in the placebo group had improved total thoracic compliance on day 8 (p ϭ .048) without adjustment for multiple comparisons.
Clinical Outcomes. Hospital mortality (Fig. 2 ) was 22.0% in the fish oil group and 20.4% in the placebo group (p ϭ .65). We also assessed 60-day mortality (Fig. 2) but were unable to contact one patient in the fish oil group (lost to follow-up) and four patients in the placebo group (one patient withdrawn and three patients lost to follow-up). Among the 85 patients with available data, mortality 14) Ϫ2 (Ϫ26 to 9) .04 0 (Ϫ2 to 33) 16 (0 to 50) . 38 
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Data are presented as median(interquartile range). Data are presented as median (interquartile range). Ventilator-free and ICU-free days through day 28, hospital length of stay, and worst multiple organ dysfunction score through day 28 are shown in Figure  2 . There were no significant differences in these outcomes between the two treatment arms.
Adverse Events. There were 14 severe adverse events in the fish oil group and 15 severe adverse events in the placebo group (Table 6) , none of which were determined to be related to the study. There were no severe adverse bleeding events in the fish oil group. One patient in the placebo group developed a retroperitoneal hematoma.
DISCUSSION
With prior studies suggesting that enteral formulas containing -3s may benefit patients with ALI and sepsis (6 -8) , this phase II double-blind placebocontrolled RCT was designed to determine the efficacy of enteral fish oil alone in reducing pulmonary and systemic inflammation in patients with ALI. Although we demonstrated that enteral -3s are easily delivered apart from enteral feeding, absorbed well, and safe in critically ill patients, we did not find a decrease in markers of pulmonary or systemic inflammation. Enteral fish oil did not lead to a clear decrease in any BALF or plasma inflammatory biomarkers, including our primary end point IL-8. Our analyses found that LTB 4 increased in the fish oil group and decreased in the placebo group. The reasons for these LTB 4 changes are not clear, and these results should be interpreted with caution because we did not adjust for multiple comparisons. Additionally, we did not find any differences in organ failure, ventilatorfree days, ICU-free days, or mortality.
There are several possible explanations for why our results conflict with prior literature. First, our study is the first investigation of -3s in patients with ALI to administer a true inert placebo to the control group. Although prior studies of fish oil-containing formulas used an isonitrogenous high-fat formula as a control, we administered enteral saline to our control group. Therefore, it may be that a high-fat control enteral formula in the prior studies was actually harmful, thus allowing the results to appear as though the -3 formula was efficacious. Second, it is possible that -3s are not the beneficial agent, but rather other ingredients in the fish oil-containing formulas such as ␥-linoleic acid or antioxidants. Third, perhaps a combination of ingredients is actually beneficial instead of a single agent. Fourth, there are no dosing data on -3s in this population. Therefore, although the dose we used is approximately 25% greater than the EPA dose received by participants in the prior studies of the commercial enteral formula, we cannot be sure that it was the optimal dose. Fifth, we delivered the fish oil as a small 7.5-mL bolus every 6 hrs, whereas prior studies delivered it continuously in enteral feeding. Sixth, our study population was substantially different from that of other ALI clinical trials (28, 48) in that a high proportion of patients had trauma as their ALI risk factor. This feature occurred because the site enrolling the most participants is an urban level I trauma center. Because patients with trauma-associated ALI have less severe endothelial and alveolar epithelial lung injury, and improved clinical outcomes, compared with patients with sepsis or another nontrauma ALI risk factor (37) , it is possible that our intervention designed to reduce pulmonary inflammation was less effective in trauma patients. Indeed, there was a suggestion in our data that BALF levels of IL-8 among trauma patients receiving fish oil increased between baseline and day 4, whereas levels decreased in both trauma patients receiving placebo and in nontrauma patients receiving either fish oil or placebo. Additionally, increases in plasma vWF, a marker of endothelial injury (38) , between baseline and day 4 were greater in trauma patients receiving fish oil than in those receiving placebo.
However, perhaps most important is the setting of our trial in an era of relatively improved care for patients with ALI. Levels of both BALF and plasma in- flammatory mediators in this RCT were substantially decreased, even severalfold, compared with prior studies in similar patients with ALI (30, 49, 50) . These decreased levels may be explained by different populations or assay methods between studies. However, a more likely explanation is that various processes of care have led to reduced lung inflammation in patients with ALI, especially in the era of low tidal volume ventilation. Survival of patients with ALI has improved over the past decades (2, 51, 52) . Reasons for this increased survival are unknown but may be the result of improved overall care, including early antibiotic administration, early goal-directed fluid resuscitation, and stress ulcer prophylaxis (53) (54) (55) . Furthermore, low tidal volume ventilation, an intervention that decreases both lung and systemic inflammation as well as mortality (28, 30, 56) , is now the standard of care in patients with ALI. If all of these interventions have resulted in reduced BALF and plasma inflammatory biomarkers, conducting appropriate phase II clinical trials with these biologic end points then becomes more difficult and requires much larger sample sizes. Furthermore, although it is known that low tidal volume ventilation decreases pulmonary inflammation, it is unclear if other interventions such as -3s are also able to further reduce lung inflammation in the setting of lung protective ventilation. The prior trial by Gadek and colleagues (6) found that patients with ALI receiving the commercial enteral formula had decreased BALF IL-8 compared with patients receiving the control formula. However, that study was conducted before lung protective ventilation was standard of care, and baseline and subsequent levels of BALF biomarkers in that study were substantially greater than in our trial. There are some limitations to our trial. First, because our population has a high proportion of trauma patients, and as is true in many critical care RCTs, many screened patients were excluded as shown in Figure 1 , generalizability of our results may be limited. Second, the number of patients in our trial was modest (n ϭ 90). Therefore, we had statistical power to detect only a relatively large difference in the primary end point, BALF IL-8, and in other inflammatory mediators. Thus, our results cannot exclude a small to moderate beneficial effect of fish oil on lung inflammation.
Our results are somewhat consistent with the OMEGA trial (trial of omega-3 fatty acid, gamma-linolenic acid and antioxidant supplementation in the management of acute lung injury), a large phase III RCT conducted by the National Heart, Lung and Blood Institute ARDS Network to investigate an enteral supplement (delivered twice daily) containing EPA, DHA, ␥-linoleic acid, and antioxidants in patients with ALI (this trial remains unpublished but results were presented at the 2009 American Thoracic Society International Conference in San Diego, CA [57] ). The control group in that study received an isocaloric amount of a standard enteral feeding formula; thus, calories received were the same between the two groups, but not fat or protein. The primary end point of OMEGA was ventilator-free days, and the planned sample size was 1000. This RCT was stopped for futility in March 2009 after accrual of 272 patients. There was no difference between the intervention and control groups with regard to ventilatorfree days, ICU-free days, or mortality at 60 days. Our study is different from OMEGA in that we used fish oil alone rather than a cocktail containing several ingredients and we used a saline placebo, but it is interesting that both our study and OMEGA found no benefit, whereas prior studies of -3s had demonstrated improved outcomes with the enteral formula containing fish oil.
CONCLUSIONS
This phase II RCT of enteral fish oil in patients with ALI did not demonstrate a decrease in pulmonary or systemic inflammatory mediators. Similarly, we did not find a decrease in ventilator-free days, ICU-free days, organ failure, or mortality. Although our findings contradict prior studies that suggest benefit of an enteral formula containing fish oil, they are consistent with those of a phase III RCT recently stopped for lack of efficacy. Omega-3s have many anti-inflammatory properties and future research is needed to determine why results of various studies over the past decade, including ours, are discordant.
